Military gives Acorda $2.67M for test of spinal cord treatment

01/25/2013 | Genetic Engineering & Biotechnology News

The Army Medical Research and Material Command awarded Acorda Therapeutics a contract worth $2.67 million to support clinical development of AC105, a magnesium-based treatment, as a therapy for acute spinal cord injuries. The contract will support a midstage trial to evaluate AC105's safety and tolerability.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA